Pituitary Adenoma in Japan: Symptoms, Causes & Treatment

Pituitary Adenoma in Japan: Symptoms, Causes & Treatment | aihealz

§ 02

How you might notice it

01Headache, often retro-orbital or bitemporal, present in 40-60% of patients with macroadenomas from dural stretch or cavernous sinus invasion.

02Bitemporal hemianopia (loss of peripheral vision in both eyes) from compression of the optic chiasm by a suprasellar extension of the adenoma — classic finding in macroadenomas.

03Galactorrhea (milk discharge from breasts in non-pregnant women or in men) and irregular menstruation or amenorrhea in women with prolactinoma.

04Loss of libido, erectile dysfunction, and decreased facial/body hair in men with hyperprolactinemia or secondary hypogonadism from any adenoma.

05Acromegaly features: increasing shoe and ring size, coarsening facial features (prominent jaw, enlarged nose and lips), excessive sweating, large hands and feet, joint pain, hypertension, sleep apnea, and new diabetes — from growth hormone excess.

06Cushing's syndrome features from ACTH-secreting adenoma: central obesity with thin extremities, moon facies, purple striae, easy bruising, proximal muscle weakness, hypertension, diabetes, osteoporosis, and mood instability.

07Diplopia (double vision) and other cranial nerve palsies from cavernous sinus invasion or apoplexy — affects nerves III, IV, V1, V2, VI.

08Symptoms of hypopituitarism: fatigue, cold intolerance, weight gain, hair loss, low blood pressure, low libido from compression of normal pituitary tissue.

09Diabetes insipidus (excessive urination and thirst) — uncommon at diagnosis but more common after surgery; results from posterior pituitary dysfunction.

10Sudden severe headache, vision loss, ophthalmoplegia, and altered mental status — pituitary apoplexy, an emergency requiring urgent evaluation.

early warning signs

•New persistent headache not responding to typical analgesics
•Subtle peripheral vision loss noticed when driving or in side mirrors
•Galactorrhea or menstrual irregularity in a non-pregnant woman
•Loss of libido, erectile dysfunction, or unexplained infertility in a man
•Increasing shoe or ring size, new sleep apnea, or facial coarsening in an adult — possible acromegaly

● emergency signs

•Sudden severe headache with vision loss, ophthalmoplegia, or altered mental status — pituitary apoplexy; emergency MRI and endocrine stress-dose steroid
•Acute adrenal crisis (hypotension, vomiting, confusion) in a patient with known or suspected hypopituitarism — IV hydrocortisone 100 mg immediately
•Acute visual loss in one or both eyes — urgent neurosurgical and neuro-ophthalmology evaluation
•Hypertensive emergency, cardiomyopathy, or severe sleep apnea in acromegaly — multidisciplinary management
•Severe hypokalemia, marked hyperglycemia, infection, or psychosis in untreated Cushing's disease — urgent inpatient stabilization

§ 03

How it’s diagnosed

diagnosis

Evaluation starts with the clinical syndrome: hormone-excess features (galactorrhea, acromegaly, Cushing's syndrome, central hyperthyroidism), hormone-deficiency features (hypopituitarism), or mass-effect features (headache, visual field loss, cranial nerve palsy). Hormone testing includes serum prolactin (with dilution to exclude hook effect in very high values), IGF-1 and oral glucose tolerance test with growth hormone suppression for acromegaly, late-night salivary cortisol and 24-hour urine free cortisol or dexamethasone suppression test for Cushing's, free T4 with TSH for central hyperthyroidism or hypothyroidism, LH/FSH and gonadal steroids, and morning cortisol for adrenal axis. Baseline pituitary panel for any adenoma includes prolactin, free T4, TSH, ACTH, cortisol, LH/FSH, estradiol or testosterone, IGF-1, and serum sodium and osmolality. MRI of the pituitary with thin sections, dynamic contrast enhancement, and dedicated coronal and sagittal views is the imaging gold standard; CT is used when MRI is contraindicated. Visual field testing by automated perimetry (Humphrey, Octopus) is performed in any patient with a tumor near the optic chiasm. The Knosp grade rates cavernous sinus invasion (0-4) and influences surgical resectability. Petrosal sinus sampling (IPSS) is used to localize ACTH source when biochemistry confirms Cushing's but MRI is negative or equivocal. Genetic testing is recommended for early-onset (under 30), familial, or aggressive adenomas. Multidisciplinary pituitary clinic review by endocrinology, neurosurgery, neuro-ophthalmology, and radiation oncology produces an integrated plan.

Key tests

Comprehensive pituitary hormone panelIdentifies hormone excess and deficiency states essential for tumor classification and management planning

Pituitary MRI with thin-section dynamic contrast (Sella protocol)Gold standard for adenoma size, extension, optic chiasm involvement, cavernous sinus invasion, and Knosp grading

Automated visual field testing (Humphrey perimetry)Detects bitemporal hemianopia or quadrant defects from optic chiasm compression, an indication for surgery in macroadenomas

Late-night salivary cortisol or 24-hour urine free cortisolInitial screening for Cushing's syndrome — confirmed by 1 mg overnight dexamethasone suppression test

Oral glucose tolerance test with growth hormone (OGTT-GH) for acromegalyConfirms acromegaly when IGF-1 elevated and clinical features present

Inferior petrosal sinus sampling (IPSS) for Cushing's localizationDifferentiates pituitary from ectopic ACTH source when biochemistry confirms Cushing's but MRI is negative or shows a microadenoma <6 mm without clear lateralization

Genetic testing for MEN1, AIP, PRKAR1A, othersIdentifies hereditary syndromes guiding family screening and surveillance

Outlook

Most pituitary adenomas are benign and amenable to effective treatment. Prolactinoma: 80-90% achieve normal prolactin with cabergoline; long-term remission off treatment after 2-3 years achieved in 30-40% of patients with sustained normalization and no residual tumor on MRI. Non-functioning macroadenoma: gross total resection 50-80% at first surgery; tumor recurrence rate 10-30% over 10 years, often controlled by stereotactic radiosurgery. Acromegaly: surgical remission rates 70-90% for microadenomas, 40-60% for macroadenomas; combined surgery and medical therapy achieves biochemical control in 80-90%. Mortality in untreated acromegaly is 2-3× general population from cardiovascular and metabolic causes; effective treatment normalizes life expectancy. Cushing's disease: surgical remission 70-90% in microadenomas, 60-70% in macroadenomas; recurrence in 15-30% over 10 years. Untreated Cushing's has 5-year mortality up to 50%; treated, mortality approaches that of general population. Hypopituitarism develops in 20-40% over 10 years after surgery or radiotherapy and requires lifelong hormone replacement. Pituitary carcinoma is rare (under 0.2%) but aggressive. Aggressive (refractory) PitNETs by 2022 WHO terminology may require chemotherapy (temozolomide) or experimental approaches.

§ 05

Causes & risk factors

known causes

Sporadic somatic mutations in pituitary cells: Most pituitary adenomas (95%) are sporadic and develop from somatic mutations in genes regulating hormone production and cell proliferation. GNAS mutations cause approximately 40% of acromegaly cases; USP8 and USP48 mutations are found in 30-60% of Cushing's disease microadenomas. The mutations produce monoclonal expansion of a single hormone-producing cell type.
Multiple endocrine neoplasia type 1 (MEN1): Autosomal dominant syndrome from MEN1 gene mutations affecting menin protein. Approximately 40% of MEN1 patients develop pituitary adenoma, most often prolactinoma or non-functioning macroadenoma. Other MEN1 tumors: parathyroid (most common), gastroenteropancreatic neuroendocrine tumors. Genetic testing recommended for first-degree relatives.
Familial isolated pituitary adenoma (FIPA) syndromes: AIP gene mutations account for 15-30% of familial pituitary adenomas, often producing somatotroph and lactotroph adenomas in younger patients (often before age 30) with more aggressive behavior. Genetic testing recommended in early-onset acromegaly or family history.
Carney complex and McCune-Albright syndrome: Carney complex (PRKAR1A mutations) causes spotted skin pigmentation, cardiac myxomas, and pituitary adenoma (often acromegaly). McCune-Albright syndrome (somatic mosaic GNAS mutations) causes café-au-lait spots, fibrous dysplasia, precocious puberty, and acromegaly.
DICER1 syndrome and SDHB/SDHD mutations: Recently recognized pediatric pituitary blastoma syndrome from DICER1 mutations. SDHB/SDHD mutations classically cause paraganglioma but also rare pituitary adenomas.
Idiopathic — no identifiable cause: In most sporadic adenomas, no identifiable risk factor is found. Pituitary adenomas are not consistently linked to environmental or lifestyle exposures; radiation exposure (e.g., for childhood cancer) modestly increases lifetime adenoma risk.

risk factors

Female sex (for prolactinoma and Cushing's disease)non-modifiable: Prolactinoma is 3-5× more common in women under age 50; Cushing's disease is 3× more common in women. Non-functioning adenomas affect men and women equally.
Multiple Endocrine Neoplasia type 1 (MEN1)genetic: Approximately 40% of MEN1 patients develop pituitary adenoma. Familial cascade screening identifies relatives at risk; periodic biochemical and MRI screening from late childhood.
Familial isolated pituitary adenoma (AIP mutation)genetic: Accounts for 15-30% of familial pituitary adenomas with early onset and aggressive course. Genetic testing recommended in early-onset acromegaly or pituitary adenoma in patients under 30 with family history.
Carney complex (PRKAR1A mutation)genetic: Includes spotty skin pigmentation, cardiac myxomas, and acromegaly. Linked to other endocrine tumors. Genetic testing in suspected syndromic patients.
Childhood cranial radiation exposureenvironmental: Cranial radiation for childhood leukemia, brain tumor, or scalp ringworm modestly increases lifetime risk of pituitary adenoma (and other CNS tumors). Risk persists for decades.
Age (varies by tumor type)non-modifiable

§ 07

When to seek help

why see a neurosurgery

Pituitary adenoma care requires close collaboration between endocrinology, neurosurgery, neuro-ophthalmology, and radiation oncology. High-volume pituitary centers achieve substantially better surgical remission rates (10-30 percentage points higher than low-volume centers) and lower complication rates. Multidisciplinary pituitary tumor boards make balanced recommendations weighing tumor characteristics and patient factors.

Find specialists →

01Hypopituitarism affecting one or more axes — develops in 20-40% over 10 years after surgery or radiotherapy; lifetime hormone replacement

02Diabetes insipidus from posterior pituitary dysfunction — transient in 10-20% post-operatively, permanent in 2-5%

03SIADH (inappropriate antidiuretic hormone) after surgery — occurs in 10-15% within 1-2 weeks of surgery, requires sodium monitoring

04Cerebrospinal fluid (CSF) leak from transsphenoidal surgery — 1-5% at experienced centers; managed with lumbar drainage or surgical repair

05Carotid artery injury (rare but life-threatening) — under 0.5% at experienced centers; requires emergency intervention

06Pituitary apoplexy in untreated macroadenoma — sudden hemorrhage or infarction with headache, vision loss, hypopituitarism

07Cardiovascular and metabolic morbidity in acromegaly and Cushing's syndrome — hypertension, diabetes, cardiomyopathy, sleep apnea, osteoporosis

choosing the right hospital

01Dedicated pituitary multidisciplinary team (endocrinology, neurosurgery, neuro-ophthalmology, radiation oncology, pathology)
02High-volume transsphenoidal surgery program (>50 cases per year per surgeon)
03Dedicated pituitary MRI protocol and reporting expertise
04Stereotactic radiosurgery capability for residual or recurrent disease
05Inpatient endocrine perioperative care with rapid cortisol and sodium monitoring

Essential facilities

Pituitary Society-recognized Pituitary Centers of ExcellenceAcademic medical centers with combined endocrine-neurosurgery pituitary clinicsTertiary skull base programs combining neurosurgery and ENTGamma Knife or CyberKnife stereotactic radiosurgery centersPituitary Network Association-affiliated patient support resources

Types and stages

Prolactinoma (lactotroph adenoma)Prolactin-secreting tumor, the most common functioning adenoma. Causes hyperprolactinemia with galactorrhea, hypogonadism (amenorrhea/infertility in women, low testosterone/erectile dysfunction in men), and bone loss. First-line treatment is dopamine agonist therapy (cabergoline, bromocriptine) which achieves prolactin normalization in 80-90% of patients and tumor shrinkage in 70-80%. Surgery is reserved for medical failure, intolerance, or apoplexy.

Non-functioning adenoma (most often gonadotroph-derived)Does not produce a clinically significant hormone excess syndrome. Presents with mass effect — visual field defect from optic chiasm compression, headache, pituitary apoplexy, or hypopituitarism. Most are macroadenomas at diagnosis. First-line treatment is transsphenoidal surgery for large or symptomatic tumors; observation is appropriate for small asymptomatic microincidentalomas.

Growth hormone-secreting adenoma (somatotroph adenoma)Causes acromegaly in adults (acral enlargement, soft tissue overgrowth, sweating, cardiomyopathy, sleep apnea, diabetes) and gigantism in children before epiphyseal closure. Surgery is first-line; medical therapy (somatostatin analogs, pegvisomant, dopamine agonists) and radiotherapy used for persistent disease. Linked to MEN1, Carney complex, and FIPA syndromes.

ACTH-secreting adenoma (corticotroph adenoma) — Cushing's diseaseCauses hypercortisolism with central obesity, moon facies, purple striae, proximal muscle weakness, hypertension, diabetes, osteoporosis, mood changes, and immunosuppression. Microadenomas predominate (>90%). Transsphenoidal surgery achieves remission in 70-90% of microadenomas at experienced centers; medical (osilodrostat, ketoconazole, mifepristone) and adrenalectomy options for persistent disease.

TSH-secreting adenoma and other rare subtypesTSH-secreting adenomas (thyrotroph) cause central hyperthyroidism with inappropriately normal or elevated TSH despite elevated free T4 and T3 — under 1% of all adenomas. Other rare types include plurihormonal adenomas and silent corticotroph adenomas (ACTH-positive on staining without clinical Cushing's). Surgery is typically first-line.

Living with Pituitary Adenoma

Timeline

Transsphenoidal surgery: hospital stay typically 2-4 days; return to most activities at 4-6 weeks; full clearance at 8-12 weeks. Vision improves often within days to weeks if optic chiasm decompression is achieved. Hormone normalization for Cushing's and acromegaly within days to weeks of successful surgery. Tumor shrinkage on dopamine agonist for prolactinoma over 3-6 months. Stereotactic radiosurgery effect on hormone secretion over 2-10 years. Lifetime monitoring required.

Lifestyle

01Take prescribed hormone replacement therapy reliably; missed doses (especially of glucocorticoid) can precipitate adrenal crisis.
02Wear a medical alert identifier indicating pituitary surgery and hormone replacement.
03Carry an emergency stress-dose hydrocortisone supply if on glucocorticoid replacement; train family members in administration.
04Attend regular endocrinology follow-up — typically every 3-6 months in the first year after treatment, then annually.
05Schedule visual field testing as advised; report any new vision change immediately.
06Manage cardiovascular risk factors aggressively in acromegaly and Cushing's syndrome — both raise cardiovascular mortality.
07Inform clinicians, dentists, and surgeons of pituitary history and any hormone replacement before procedures.

Daily management

01Take hormone replacement at the same times daily (hydrocortisone in two divided doses; thyroxine in the morning on an empty stomach).
02Use stress-dose glucocorticoid protocols for illness, surgery, dental procedures; have emergency injection available.
03Record any new headache, vision change, urinary symptoms, or fatigue and report to the team.
04For prolactinoma on cabergoline, take dose at the same time(s) each week and attend echocardiogram screening if on high cumulative dose.
05For acromegaly, monitor blood pressure and blood sugar regularly.
06Schedule and attend follow-up MRI and hormone testing per the agreed plan.

Exercise

Regular moderate aerobic activity (150 minutes per week) and resistance training (2 sessions per week) are encouraged. In acromegaly with cardiomyopathy or severe sleep apnea, exercise prescription should be reviewed with cardiology. In Cushing's syndrome with proximal myopathy and osteoporosis, supervised physical therapy initially. After transsphenoidal surgery, avoid heavy lifting and Valsalva maneuvers for 4-6 weeks to reduce CSF leak risk.

§ 08

Frequently asked

What is a pituitary adenoma?

A pituitary adenoma is a benign tumor arising from the hormone-producing cells of the pituitary gland. The 2022 WHO classification now calls these pituitary neuroendocrine tumors (PitNETs). Most are non-cancerous but can cause problems by producing excess hormones, compressing normal pituitary tissue, or pressing on nearby structures like the optic chiasm.

What are the symptoms of a pituitary tumor?

Symptoms depend on tumor type and size. Hormone excess causes specific syndromes: prolactin tumors cause menstrual changes and infertility; growth hormone tumors cause acromegaly; ACTH tumors cause Cushing's disease. Large tumors cause headache and visual loss from pressure on the optic chiasm. Some tumors are asymptomatic and found incidentally.

How common are pituitary adenomas?

Clinically relevant pituitary adenomas affect approximately 1 in 1,000-1,400 adults. Small asymptomatic lesions are found in up to 25% of adults on autopsy or imaging. Prolactinoma is the most common functioning type, especially in women under 50. Non-functioning macroadenomas peak in older adults.

What is a prolactinoma?

A prolactinoma is a prolactin-secreting pituitary adenoma. It causes high prolactin levels, leading to menstrual irregularity and infertility in women, milk discharge from breasts (galactorrhea), and low libido or erectile dysfunction in men. First-line treatment is dopamine agonist medication (cabergoline) which normalizes prolactin in 80-90%.

What is acromegaly?

Acromegaly is the clinical syndrome from excess growth hormone in adults, almost always from a pituitary adenoma. Features include enlargement of hands, feet, and facial features, sweating, joint pain, hypertension, diabetes, and sleep apnea. Untreated, it shortens life expectancy. Surgery is first-line; medical therapy and radiotherapy are used for persistent disease.

What is Cushing's disease?

Cushing's disease is hypercortisolism caused by an ACTH-secreting pituitary adenoma. Features include central obesity, moon face, purple stretch marks, muscle weakness, hypertension, diabetes, osteoporosis, and mood changes. Transsphenoidal surgery is first-line, achieving remission in 70-90% of microadenomas in expert centers.

What is the difference between a microadenoma and macroadenoma?

Microadenomas are less than 10 mm in diameter and rarely cause mass effect — usually present with hormone excess. Macroadenomas are 10 mm or larger and commonly cause headache, visual loss, and hypopituitarism. Giant adenomas (40 mm or larger) carry higher surgical complexity and lower remission rates.

How is a pituitary adenoma diagnosed?

Diagnosis combines hormone testing (prolactin, IGF-1, cortisol, ACTH, thyroid hormones, gonadotropins), pituitary MRI with thin sections and contrast, and visual field testing if the tumor approaches the chiasm. Specialized tests (dexamethasone suppression, oral glucose tolerance test, petrosal sinus sampling) confirm specific hormonal syndromes.

What is transsphenoidal surgery?

Transsphenoidal surgery is a minimally invasive approach to the pituitary gland through the nose and sphenoid sinus. Modern endoscopic transsphenoidal surgery has hospital stays of 2-4 days and high remission rates for Cushing's disease (70-90% microadenoma), acromegaly (70-90% microadenoma), and visual recovery for chiasmal compression.

Do all pituitary tumors need surgery?

No. Prolactinomas are usually treated with dopamine agonist medication (cabergoline) rather than surgery. Small non-functioning microadenomas without symptoms are observed with serial MRI. Surgery is first-line for most other secretory tumors and for macroadenomas causing visual loss or hypopituitarism.

Are pituitary adenomas cancerous?

Almost all pituitary adenomas are benign. The 2022 WHO classification renamed them pituitary neuroendocrine tumors (PitNETs). Pituitary carcinoma — with metastasis outside the central nervous system — is very rare (under 0.2%). Some adenomas behave aggressively with rapid growth or recurrence and are called aggressive PitNETs.

What is pituitary apoplexy?

Pituitary apoplexy is sudden hemorrhage or infarction of a pituitary adenoma, causing acute severe headache, visual loss, eye movement abnormalities, and hypopituitarism. It is a medical emergency requiring urgent imaging, stress-dose hydrocortisone, and consideration of urgent surgical decompression if vision is threatened.

Will I need lifelong medication after pituitary surgery?

It depends on outcomes. If the entire tumor is removed and the rest of the pituitary works, no replacement is needed. Many patients require permanent replacement of one or more hormones (cortisol, thyroid, sex hormones, growth hormone, antidiuretic hormone). Regular endocrinology follow-up is lifelong.

Can a pituitary adenoma cause infertility?

Yes. Prolactinoma suppresses ovulation in women and testosterone in men; hypopituitarism from macroadenoma compression has similar effects. Treatment of the tumor with cabergoline or surgery often restores fertility, sometimes within months. Specialized reproductive endocrinology support is valuable for persistent infertility.

Can children get pituitary adenomas?

Yes. Prolactinoma can occur in adolescence; growth hormone-secreting adenoma causes gigantism in children before epiphyseal closure. Pediatric pituitary adenomas are more often syndromic (MEN1, AIP, Carney complex, McCune-Albright) and warrant genetic evaluation. Care should be at experienced pediatric pituitary centers.

Is pituitary adenoma hereditary?

Most are sporadic. About 5% are hereditary: multiple endocrine neoplasia type 1 (MEN1), familial isolated pituitary adenoma (AIP gene), Carney complex (PRKAR1A), McCune-Albright syndrome, and DICER1 syndrome. Genetic testing is recommended for adenoma onset under 30, aggressive disease, or family history.

What is the success rate of transsphenoidal surgery?

Outcomes vary by tumor type. Cushing's disease remission 70-90% in microadenomas; acromegaly remission 70-90% in microadenomas, 40-60% in macroadenomas; non-functioning macroadenoma gross total resection 50-80% depending on cavernous sinus invasion. Outcomes are substantially better at high-volume pituitary centers.

What is stereotactic radiosurgery for pituitary tumors?

Stereotactic radiosurgery (Gamma Knife or CyberKnife) delivers a single high-dose treatment of focused radiation. It is used for residual or recurrent adenoma after surgery, or in patients unfit for surgery. Hormone control develops over 2-10 years; risk of new hypopituitarism over 10 years is 20-40%.

Does pregnancy affect pituitary adenomas?

Prolactinoma can enlarge during pregnancy from estrogen stimulation; small microadenomas usually remain stable but macroadenomas may need monitoring. Cabergoline is generally stopped at confirmed pregnancy and restarted if symptoms recur. Acromegaly and Cushing's disease pregnancies require specialist multidisciplinary management.

What is the difference between Cushing's syndrome and Cushing's disease?

Cushing's syndrome is the clinical state of hypercortisolism from any cause. Cushing's disease specifically refers to an ACTH-secreting pituitary adenoma as the cause. Other causes of Cushing's syndrome include adrenal tumor, ectopic ACTH from non-pituitary tumors (e.g., small cell lung cancer), and prolonged exogenous glucocorticoid therapy.

How is pituitary adenoma follow-up done?

Follow-up combines hormonal testing and pituitary MRI. After successful surgery, MRI is typically at 3-6 months, 1 year, then annually for several years. Hormonal axes are tested 6-12 weeks after surgery and at follow-up visits. Long-term lifelong endocrinology surveillance detects recurrence and emerging hypopituitarism.

Pituitary Adenoma.Care & specialists in Japan

What it is

How you might notice it

How it’s diagnosed

Treatment & cost

Causes & risk factors

Living with it

When to seek help

Related conditions

Easily confused with

Often appears alongside

Types and stages

Living with Pituitary Adenoma

Complementary approaches

Patient support resources

Frequently asked

Sources & references

Top Neurosurgerys in Japan.

Connect with top Neurosurgerys in Japan.